- Home
- SLI vs AUTL Comparison
SLI vs AUTL Comparison
Compare SLI & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLI
- AUTL
- Stock Information
- Founded
- SLI 1998
- AUTL 2014
- Country
- SLI Canada
- AUTL United Kingdom
- Employees
- SLI N/A
- AUTL N/A
- Industry
- SLI Major Chemicals
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLI Industrials
- AUTL Health Care
- Exchange
- SLI Nasdaq
- AUTL Nasdaq
- Market Cap
- SLI 355.5M
- AUTL 359.3M
- IPO Year
- SLI N/A
- AUTL 2018
- Fundamental
- Price
- SLI $1.70
- AUTL $2.36
- Analyst Decision
- SLI Buy
- AUTL Strong Buy
- Analyst Count
- SLI 1
- AUTL 5
- Target Price
- SLI $4.40
- AUTL $9.32
- AVG Volume (30 Days)
- SLI 2.3M
- AUTL 2.5M
- Earning Date
- SLI 06-17-2025
- AUTL 05-08-2025
- Dividend Yield
- SLI N/A
- AUTL N/A
- EPS Growth
- SLI N/A
- AUTL N/A
- EPS
- SLI N/A
- AUTL N/A
- Revenue
- SLI N/A
- AUTL $9,011,000.00
- Revenue This Year
- SLI $33.34
- AUTL $371.59
- Revenue Next Year
- SLI N/A
- AUTL $165.71
- P/E Ratio
- SLI N/A
- AUTL N/A
- Revenue Growth
- SLI N/A
- AUTL N/A
- 52 Week Low
- SLI $1.07
- AUTL $1.11
- 52 Week High
- SLI $2.64
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- SLI 57.34
- AUTL 81.27
- Support Level
- SLI $1.49
- AUTL $2.04
- Resistance Level
- SLI $1.94
- AUTL $1.79
- Average True Range (ATR)
- SLI 0.12
- AUTL 0.13
- MACD
- SLI -0.01
- AUTL 0.09
- Stochastic Oscillator
- SLI 47.19
- AUTL 94.66
About SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.